Development of Skin-Humanized Mouse Models of Pachyonychia Congenita  by García, Marta et al.
Development of Skin-Humanized Mouse Models
of Pachyonychia Congenita
Marta Garcı´a1,2,6, Fernando Larcher1,2,6, Robyn P. Hickerson3, Eulalia Baselga4, Sancy A. Leachman5,
Roger L. Kaspar3 and Marcela Del Rio1,2
Molecular characterization and assessment of therapeutic outcomes for inherited cutaneous disorders requires
faithful preclinical models. In this study we report the establishment of two different skin-humanized
pachyonychia congenita (PC) model systems, based on permanent engraftment of bioengineered skin
equivalents generated from patient skin cells onto immunodeficient mice. Using keratinocytes and fibroblasts
isolated from unaffected skin biopsies of two PC patients carrying the p.Asn171Lys mutation of the keratin 6a
gene (KRT6A), we were able to regenerate PC-derived human skin that appeared phenotypically normal, but
developed sustained PC features after the use of an acute hyperproliferative stimulus (i.e., tape stripping). In
contrast, the use of keratinocytes from an affected area (i.e., plantar callus) from a different patient carrying the
KRT6A mutation p.Asn171Asp led to a full recapitulation of the phenotype that included marked acanthosis and
epidermal blistering after minor trauma. The ability to generate large numbers of PC skin-engrafted mice will
enable the testing of novel pharmacological or gene-based therapies for this as yet untreatable disease.
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INTRODUCTION
During the last decade, substantial progress has been made
in determining the genetic basis of several inherited skin
diseases (Lane and McLean, 2004). Pachyonychia congenita
(PC) is a rare autosomal dominant keratin disorder character-
ized by thickened and dystrophic nails as well as painful
palmoplantar keratoderma and blisters on or near the
pressure points of the feet (Leachman et al., 2005;
Smith et al., 2006). PC is caused by dominant-acting
mutations (mainly point mutations and small in-frame
insertion/deletion mutations) in any one of the genes
encoding the differentiation-specific and stress-inducible
keratins, K6a, K6b, K16, or K17 (Bowden et al., 1995;
McLean et al., 1995; Smith et al., 1998). These mutations are
usually found in hot spots located near the start and end
of the a-helical rod domain, regions of the keratin molecule
that are critically important for polymerization (Smith et al.,
2005). The mutant keratins act in a dominant-negative
manner, resulting in defective intermediate filament forma-
tion and, ultimately, appear to be responsible for all of the
epithelial fragility symptoms associated with PC. Detailed
analyses of the keratin mutations found in PC are presented in
an accompanying article (Wilson et al., 2011).
Although mouse models involving the PC-related keratin
genes have been described, the various gene-targeting
strategies applied to alter the function of relevant keratins in
transgenic animals elicit only a subset of minor PC-specific
epithelial lesions (Chen and Roop, 2005; Wong et al., 2005;
Chen et al., 2008). Importantly, the existing genetically
modified mouse models of PC differ from the human
condition in that the former are based on knockout of keratin
genes (i.e., these are recessive, loss-of-function alleles),
whereas the human PC mutations are dominant negative
(Smith et al., 2005; Wilson et al., 2011). However, although a
transgenic mouse expressing a mutant krt75 (K6hf) (Chen
et al., 2008) recapitulates many of the hair and nail defects of
PC, an equivalent mutation has not been found in any of the
PC patients. In addition, differences in cutaneous anatomy
between mice and humans are problematic in achieving
trustworthy models to study actual genotype–phenotype
associations or to assess therapeutic strategies. Finally, a
current approach to therapy in the keratin disorders is that of
allele-specific gene silencing using small interfering RNA
(Hickerson et al., 2008; Leachman et al., 2008, 2010). Owing
to differences in DNA sequence between human and mouse,
a humanized model system is required to test this type of
highly sequence-dependent therapy.
The use of optimized tissue engineering strategies has
been successful in modeling acquired or inherited human
skin disorders (Escamez et al., 2004; Gache et al., 2004;
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Spirito et al., 2006). A system based on the deconstruction–-
reconstruction of the disease through skin biopsy, keratino-
cyte, and fibroblast culture (deconstruction), followed by
bioengineered skin preparation and grafting on immunodefi-
cient mice (reconstruction) can be applied to generate a large
number of mice engrafted with homogeneous normal or
diseased human skin (Garcia et al., 2007). In fact, we have
developed a reliable preclinical humanized model of the
genodermatosis dystrophic epidermolysis bullosa, which is
amenable to gene correction in a clinically relevant system
(Gache et al., 2004).
In this study we report the establishment of a tissue
engineering-based humanized model of PC. Starting from a
skin biopsy of an uninvolved area of two PC patients (both
carrying the K6a mutation p.Asn171Lys), we demonstrate
epidermal phenotypic changes following induction of a
hyperproliferative response in the engrafted tissue, consistent
with PC features. Moreover, the use of keratinocytes from
affected skin from a third patient carrying a different amino
acid substitution in the same codon of the K6a gene resulted
in the development of a constitutively expressed, bona fide
PC phenotype. The humanized PC models described are
amenable to genetic intervention as recently shown in PC
patients (Leachman et al., 2010).
RESULTS
Development of a hyperproliferation-dependent PC model
Skin punch biopsies obtained from nonlesional buttock skin
areas of two PC patients harboring the K6a mutation
p.Asn171Lys were used to isolate keratinocytes and fibro-
blasts. PC patient-derived cells grew at similar rates and
exhibited similar morphological characteristics as age-
matched normal skin cells (data not shown). Bioengineered
PC skin equivalents were grafted onto immunodeficient nu/
nu mice. After 8 to 10 weeks of grafting (the period of time
needed to obtain mature regenerated human skin; Del Rio
et al., 2002; Llames et al., 2004), the recipient mice exhibited
patchy pigmented human skin, which is likely because of
melanocyte carryover in the keratinocyte culture (Figure 1).
Macroscopically, the engrafted PC human skin was similar
to the control human skin (Figure 1). At the histological level,
some slight differences were observed in the PC-derived skin
compared with the control, particularly with regard to
increased compact hyperkeratosis of the stratum corneum,
which was more prominent in the PC-regenerated skin
(Figure 1). As in native normal human skin and uninvolved
PC skin biopsies from nonpalmoplantar sites, K16 was not
expressed in normal or PC-regenerated skin (Figure 1).
Consistent with a mature and well-differentiated epidermis,
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Figure 1. Clinical and histopathological features of human pachyonychia
congenita (PC) skin regenerated from KRT6A p.Asn171Lys mutant
buttock-derived non-PC cells. (a) Clinical appearance of engrafted mice.
Normal (left panel) and PC-regenerated skin (right panel) on immunodeficient
mice at 12 weeks after grafting. Arrowheads delimit the engrafted areas.
(b) Histopathological characteristics of PC-regenerated skin grafts.
PC-regenerated skin on immunodeficient mouse host (panels on the right)
shows similar histopathological and marker features when compared with
normal regenerated skin (panels on the left). (b.1, b.2) Hematoxylin and eosin
(H&E) staining of normal skin; (b.3, b.4) loricrin immunoperoxidase staining;
(b.5, b.6) K10 immunostaining; (b.7, b.8) human-specific involucrin
immunoperoxidase staining (hu, human skin; mo, mouse skin); and
(b.9, b.10) K16 inmunoperoxidase staining. Bars¼ 100mm.
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K10, loricrin, and involucrin exhibited typical expression
patterns (Figure 1), both in normal and PC-regenerated skin.
The human origin of the engrafted tissue was confirmed using
a monoclonal antibody specific for human involucrin that
does not recognize mouse tissue (Figure 1, panel b.7).
With the aim of identifying conditions that might better
recapitulate the hyperkeratotic PC phenotype, both normal
and PC skin-engrafted mice were subjected to an abrasive
‘‘wound-like’’ treatment (i.e., tape stripping), which is known
to generate a hyperproliferative response with a concomitant
expression of keratins K6/K16 (Ramirez et al., 1995). As
expected, analysis of both normal and PC grafts following
tape stripping revealed skin thickening that, at the histologi-
cal level, was observed to consist of acanthosis and K6/K16
induction (Figure 2). A time course and quantitative analysis
of hyperproliferation-associated changes occurring after tape
stripping showed that at 72, 168, and 360hours after
stripping, the response of engrafted PC skin in terms of
epidermal thickening, rete ridge abnormalities, and K16
expression was more pronounced and sustained than that
observed in normal, regenerated human skin at all time
points (Figure 2). An analysis of epidermal differentiation
markers 168 hours after tape stripping, the time point where
epidermal thickening reaches a maximum in PC grafts,
showed remarkable differences with respect to controls
(Figure 2). For example, immunostaining for the differentia-
tion marker, K10, which is uniformly expressed in the
suprabasal layers of the epidermis (Figure 2b), showed a
reduced and patchy expression in PC-regenerated skin
(Figure 2b). Concomitantly, suprabasal expression of keratin
K16 appeared to occur also in patches in the PC skin-derived,
but not in normal skin-derived tape-stripped skin, suggesting
a contribution of the aberrant K6/K16 expression to the
pathogenesis of PC (Figure 2b). Remarkably, loricrin, a major
terminal differentiation marker that is normally located in the
granular layer (Figure 2b), displayed an altered pattern of
staining, being negative in the hyperplastic areas in PC skin
(Figure 2b). These results are consistent with the maintenance
of an active hyperproliferative-like status, as well as persistent
(and likely aberrant) K6/K16 protein expression in the PC graft
(Figure 2).
Furthermore, although the kinetics of the hyperprolifera-
tive response (as determined by Ki67 expression) were similar
in normal and PC grafts, the number of labeled nuclei in PC
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Figure 2. Development of a hyperplastic response in normal and pachyonychia congenita (PC)-regenerated human skin after tape stripping. Both normal and
PC-regenerated human skin develop a hyperplastic phenotype following tape stripping. (a) Time course histopathological analysis and K6 induction.
Hematoxylin and eosin (H&E) staining of normal and PC-regenerated skin sections at (a.1, a.2) 0, (a.5, a.6) 72, and (a.9, a.10) 360 hours. Keratin K6
immunoperoxidase staining of normal and PC-regenerated skin sections at (a.3, a.4) 0, (a.7, a.8) 72, and (a.11, a.12) 360 hours. (b) Hyperplastic response and
epidermal differentiation marker abnormalities 168 hours following tape stripping. (b.1, b.5) H&E staining of normal and PC-regenerated skin sections. Keratin
K16 induction as determined by alkaline phosphatase immunostaining in (b.2) normal and (b.6) PC-regenerated skins. K10 immunostaining in (b.3) normal
and (b.7) PC-regenerated skins. Loricrin immunoperoxidase staining in (b.4) normal and (b.8) PC-regenerated skins. Note that K16 is no longer expressed in
(b.2) normal regenerated skin but maintained in (b.6) PC skin, and also the reduced expression of K10 and absence of loricrin expression in the acanthotic,
K16-positive areas in PC skin. Bar¼ 100mm.
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skin grafts (at peak value) was significantly higher (61 vs. 30
at 72 hours, Po0.05; Figure 3a and b). Moreover, epidermal
acanthosis, the phenotypic consequence of hyperprolifera-
tion, was consistently exacerbated in PC skin grafts relative to
normal tape-stripped controls at all time points (Figure 3a and
c), in spite of an attenuation of the hyperproliferative
response observed in both PC and control grafts. Expression
of wild-type and mutant (p.Asn171Lys) K6a mRNA levels
were assayed in untreated and tape-stripped (24-hour time
point) human PC grafts. The results shown in Figure 3d
demonstrate that both wild-type and mutant K6a mRNA
levels are identically induced following tape stripping
(18-fold increase). A similar induction of K16 was observed
(21-fold increase), consistent with K16 being a poly-
merization partner of K6a. This result indicates that the
phenotypic changes observed at the protein level (i.e.,
aberrant patchy distribution) are likely because of the
induction of the mutant K6a.
Development of a spontaneous model faithfully recapitulating PC
The results obtained with cells derived from a nonlesional
biopsy site where K6a is not constitutively expressed
permitted us to establish a clear correlation between the
induction of aberrant K6a protein and development of PC
manifestations. However, the acute hyperproliferative stimu-
lus was not sufficient to fully recapitulate the PC phenotype.
To that end, we assessed whether skin regenerated with
keratinocytes (and fibroblasts) from a plantar lesional area,
constitutively expressing K6/K16, were able to recapitulate
the main features of the disease. At 9 weeks after grafting of
plantar callus-derived PC bioengineered skin, we observed
macroscopic signs of a whitish hyperkeratosis in the human
skin grafts (Figure 4). Histopathological analysis of regener-
ated PC skin revealed the presence of a very prominent
stratum corneum (Figure 4b) as well as constitutive expres-
sion of K6 in the absence of tape stripping or other physical
insult (Figure 4c). A distinctive feature of differentiated
plantar callus-derived skin, also found in PC-regenerated
skin, was the presence of K9 (Figure 4c, inset). Expression of
K9 was not detected in PC grafts derived from buttock cells
(data not shown). In contrast to PC grafts derived from
nonlesional skin, where vigorous tape stripping induced only
epidermal acanthosis (Figures 2 and 3c), application of very
mild friction to plantar-derived PC skin developed one of the
main features of the disease, namely, extensive epidermal
blisters. Blisters occur in the lower suprabasal layers as
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Figure 3. Kinetics of hyperplasic response following tape stripping in normal and pachyonychia congenita (PC)-regenerated human skin. (a) Time
course analysis of cell proliferation (Ki67 staining) in the epidermis at 0, 72, 168, and 360 hours after wounding (tape stripping). Bar¼ 50 mm. (b) Quantitative
data of epidermal cell proliferation as shown in panel a. A minimum of 10 fields were counted for each preparation. (c) Relative increase in epidermal thickness
after tape stripping. Epidermal thickness was calculated as the distance between the top of the granular layer and the bottom of the basal layer at the indicated
time points following tape stripping. (d) Quantitative analysis of K6/K16 mRNA expression in PC-regenerated human skin. K6a (wild-type and mutant
p.Asn171Lys) and K16 mRNA levels (relative to glyceraldehyde-3-phosphate dehydrogenase (GAPDH)) were determined by quantitative real-time reverse
transcriptase-PCR (QRT-PCR) in PC human skin excised from untreated (NT) and tape-stripped engrafted mice (24-hour time point) as described in
Materials and Methods.
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demonstrated by hematoxylin and eosin staining and
immunomapping with keratin K5 that predominantly labels
basal keratinocytes in the base of the split (Figure 5c). In
summary, we have developed two complementary skin-
humanized models, one that enables characterization of the
molecular events leading to PC and a second one that more
faithfully recapitulates major histopathological features of the
disease. Both models are suitable for testing of pharmacolo-
gical and genetic therapeutic strategies.
DISCUSSION
Several clinically relevant features of PC and other genoder-
matoses can be studied in patient skin biopsies or histological
specimens. However, because experimentation with human
volunteers is limited by ethical and practical considerations,
as well as the limited number of PC patients, testing
therapeutic approaches requires living preclinical models,
which faithfully recapitulate the in vivo hallmarks of the
disease in situ (Leachman et al., 2010). Several mouse models
have been developed by gene targeting of the PC-related
keratin genes (Chen and Roop, 2005; Wong et al., 2005).
Although these mice represent excellent tools for pathogenic
and functional studies, they were not designed to model PC
and are unsuitable as preclinical models for testing therapies
for a number of reasons. First, all PC-causing mutations are
dominant negative (Wilson et al., this issue). With an
exception (Chen et al., 2008), existing mouse models
involving K6, K16, and K17 are knockout mice (McGowan
et al., 2002; Chen and Roop, 2005; Wong et al., 2005), and
therefore represent recessive-acting, null alleles that are
mechanistically unrelated to the human condition. Second,
there are several fundamental structural differences between
mouse and human skin that represent a formidable barrier for
assessment of surrogate markers of efficacy if a drug- or gene-
based therapy is to be tested. Humanized skin models
obtained through grafting human cells onto immunodeficient
mice thus offers a practical solution to development of a
highly realistic preclinical model of PC.
In this study, we established two different humanized
models of PC based on the application of an optimized
cutaneous tissue engineering approach previously used to
model other genodermatoses such as dystrophic epidermo-
lysis bullosa and junctional epidermolysis bullosa (Gache
et al., 2004; Spirito et al., 2006; Garcia et al., 2007). In the
latter models, blisters (the main features of the disease) were
apparent immediately after skin regeneration without any
external stimulus, because of the absence of functional
dermal–epidermal anchoring structures resulting from the
disease-causing mutations. In contrast, in our hyperprolifera-
tion-dependent PC model, the pathogenic mutant gene, the
p.Asn171Lys allele of K6a, must be induced by a hyperplastic
stimulus before symptoms are apparent because K6 is not
expressed constitutively in the buttock skin. Therefore,
following wounding by tape stripping, this model exclusively
recapitulates features of the disease in similar fashion to skin
areas undergoing mild abrasion or other external stress
(Leachman et al., 2005).
Although a hyperproliferation response is also observed
in normal regenerated human skin, the response in PC-
regenerated skin was characterized by stronger, more
sustained hyperplasia, as determined by epidermal thickening,
Ki67 expression, and aberrant K6/K16 protein expression. It is
thus conceivable that in our hyperproliferation-dependent PC
model, a more persistent stimulus (e.g., repeated abrasion,
ultraviolet irradiation, and so on), would be capable of
worsening the condition.
The use of keratinocytes and fibroblasts derived from
plantar callus, as applied in our second PC model, resulted in
the retention of the phenotypic features of the donor
anatomical site in the engrafted skin. These included
constitutive expression of plantar keratin markers K6 and
K9 (Moll et al., 1987). Retention of donor site-specific
phenotype after cultured epithelial grafting was observed
previously (Stoner and Wood, 1999; Mavilio et al., 2006).
Thus, the sustained expression of mutant keratin K6
is assumed to be responsible for the recapitulation of
pathognomonic signs of the disease including friction blisters.
Although the source of keratinocytes and fibroblasts appears
the most likely explanation for the establishment of a full PC
skin phenotype, we cannot rule out some genotype–pheno-
type effects. Specifically, although the plantar callus- and
buttock-derived cells come from different patients who carry
a b c
Figure 4. Clinical and histopathological features of human pachyonychia congenita (PC)-regenerated skin from affected plantar callus-derived PC cells.
(a) Macroscopic appearance of engrafted mice. (b) Hematoxylin and eosin (H&E) staining of PC graft derived from plantar callus cells. (c) Constitutive expression
of K6 in the sole-derived PC graft. Bars¼ 100mm. (Inset) Expression of K9, which is characteristic and exclusively expressed in the palmoplantar suprabasal
keratinocytes.
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different KRT6A mutations (p.Asn171Asp and p.Asn171Lys,
respectively), the phenotype of patients with these mutations
is very similar (data not shown).
Our humanized PC models, which accurately recapitulate
human PC features, should be a valuable tool for developing
robust therapeutic approaches for this genetic disorder as
better treatments evolve. In this regard, current treatment
strategies for PC are based primarily upon reduction of
symptoms through a combination of mechanical debride-
ment of nails and callus and/or through the use of nonspecific
keratolytic agents that decrease the keratin burden (Leach-
man et al., 2005; Smith et al., 2006). These treatments do not,
however, address the underlying cause of the disorder. Oral
retinoids can also be prescribed to reduce the keratoderma,
but the side-effect profile is frequently unacceptable to
patients, particularly for long-term use. Clearly, the treatment
options for PC are inadequate and, to our knowledge
previously unreported, therapeutic options are being devel-
oped including targeted molecular therapies (Leachman
et al., 2010), which will benefit from the availability of a
humanized mouse model for assessment of both efficacy and
cutaneous delivery optimization.
MATERIALS AND METHODS
Primary cultures of human keratinocytes and fibroblasts
Human keratinocytes and dermal fibroblasts were obtained by
enzymatic digestion (Llames et al., 2004) from skin samples (5-mm
punch biopsies) taken from the buttocks of two PC donor patients
(IPCC nos. 9 and 10) carrying the p.Asn171Lys mutation and from
the plantar callus of a Spanish patient (IPCC no. 245) harboring the
p.Asn171Asp mutation (see www.pachyonychia.org). Participants
gave their written informed consent for biopsies. The medical ethical
committees of Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
and Department of Dermatology, University of Utah, Salt Lake City,
UT approved all described studies. The study was conducted
according to the Declaration of Helsinki Principles. Primary
keratinocytes were cultured on a feeder layer of lethally irradiated
(X-ray; 50Gy) 3T3-J2 cells (a gift from Dr J Garlick, Tufts University)
as previously described (Rheinwald and Green, 1975).
Bioengineered PC skin preparation and grafting
Bioengineered human skin equivalents are based on the use of fibrin,
containing live fibroblasts, as the dermal component (Del Rio et al.,
2002). Briefly, 1ml of fibrinogen (from blood cryoprecipitates) was
added to 2ml of DMEM with 10% fetal calf serum containing
1.5 105 dermal fibroblasts and 250 IU of bovine aprotinin
(Trasylol; Bayer, West Haven, CT), followed immediately by the
addition of 250ml of 0.025mM CaCl2 (Sigma, St Louis, MO)
containing 11 IU of human thrombin (Sigma). This mixture was
allowed to clot at 37 1C in 35mm tissue culture well plates. After
24 hours, normal human or PC-derived keratinocytes were seeded
and allowed to grow submerged until reaching confluence. Mice
were aseptically cleansed and grafted as previously described
(Del Rio et al., 2002; Llames et al., 2004). Mice were anesthetized,
with concomitant analgesia, by intraperitoneal administration of
ketamine/metodomidine (Pfizer, Madrid, Spain) and grafted. Briefly,
full-thickness 12-mm circular wounds were then created on the
dorsum of mice to match size of the prepared skin equivalents.
Mouse skin that had been removed to generate the wound was
devitalized by three repeated cycles of freezing and thawing and
used as a biological bandage, and fixed with sutures (Mersilk 5-0;
b
c
a
Figure 5. Epidermal blister formation in pachyonychia congenita
(PC)-regenerated skin from plantar callus-derived cells. (a) Epidermal blisters
(arrows) develop in plantar callus-derived PC skin after application of mild
friction. (b) Immunoperoxidase staining of constitutive K9 in a skin section
consecutive to that in panel a. (c) Inmunoperoxidase staining of K5 showing
that cleavage occurs over the basal layer (labeled) in plantar callus-derived PC
skin after application of mild friction. A total of four mice were grafted with
plantar callus-derived PC skin. Bars¼ 50mm.
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Ethicon, Somerville, NJ) to protect and hold the skin substitute in
place during the grafting procedure. The necrotic mouse skin
overlying the graft spontaneously sloughed off, generally within 15
days of grafting, and regenerated human skin became visible.
Grafting was performed under sterile conditions, using 6-week-old
female nu/nu mice. Mice were housed in pathogen-free conditions
using individually ventilated cages (25 air changes per hour) and
10KGy g-irradiated soft wood pellets as bedding.
Tape stripping and minor trauma in PC skin-humanized mice
Ordinary paper adhesive tape (Tesa AG, Hamburg, Germany) was
applied to the stably engrafted human skin on the backs of nude
mice (9–12 weeks post grafting) by repeatedly (70 times) press-
sticking and pulling off the tape (‘‘tape stripping’’). A fresh piece of
tape was used after every 10 cycles. Following tape stripping, tissue
samples (4mm biopsy punches; Stiefel Lab, Madrid, Spain) were
collected from each mouse at 0, 24, 72, 96, 168, and 360 hours
(n¼ 2 to 3 per group). Minor blister-inducing trauma was achieved
by slight friction with a plastic pipette tip on the regenerated skin.
Biopsies were collected 15minutes later after blister induction. Skin
samples for immunohistochemistry were harvested and fixed in 3.7%
formaldehyde. After fixation, the skin biopsy was embedded in paraffin
and 4mm serial sections were generated. Samples to be used for RNA
extraction were harvested and frozen immediately in liquid nitrogen.
Histopathological analysis of engrafted human skin
All samples of human skin were analyzed by standard histological
and immunohistochemical techniques. Paraffin sections were
processed as described (Escamez et al., 2004). Briefly, formaldehyde-
fixed sections were subjected to antigen retrieval treatment and
stained using specific antibodies. The antibodies used were anti-
keratin K10 (Lab Vision, Thermo Fisher Scientific, Fremont, CA),
human-specific anti-involucrin monoclonal antibody (Clone SY5;
Sigma), polyclonal anti-loricrin (clone AF-62; Covance, San Diego,
CA), polyclonal anti-K9 (clone D-16; Santa Cruz Biotechnology,
Santa Cruz, CA), and polyclonal anti-K5 (AF 138; Covance). The
hyperplastic response was assessed through both the analysis of
epidermal cell proliferation using a specific Ki67 (Clone SP6, rabbit
monoclonal) antibody and the immunodetection of expression of
keratins K6 (LHK6B, mouse monoclonal) and K16 (Clone LL025,
mouse monoclonal) with specific antibodies (Lab Vision). Immuno-
detection was performed according to the manufacturer’s protocol.
Immunoperoxidase staining was developed using the Vectastain
ABC kit (Vector Laboratories, Burlingame, CA) and immuno-alkaline
phosphatase staining with the UltraVision LP Detection System (Lab
Vision). Epidermal thickness was calculated as the distance between
the top of the granular layer and the bottom of the basal layer.
Quantitative real-time reverse transcriptase-PCR analysis
RNA was isolated from human skin grafts using Trizol reagent (Gibco
BRL, Barcelona, Spain) and analyzed by quantitative real-time
reverse transcriptase-PCR. RNA isolated from skin samples or tissue
culture cells was reverse transcribed using the Superscript III first
strand synthesis system (Invitrogen, Carlsbad, CA) following the
manufacturer’s instructions. Briefly, 1mg of total RNA (8ml) was
incubated with random hexamer primers (5 ng ml–1, final concentra-
tion) and dNTPs (1mM, final concentration) at 65 1C for 5minutes in
a final volume of 10 ml and then placed on ice for at least 1minute.
The reverse transcription reaction was performed using 1ml Super-
script III reverse transcriptase (200Uml–1) in 1 buffer (20mM Tris-
HCl (pH 8.4), 500mM KCl, 5mM MgCl2, and 10mM dithiothreitol)
and 1ml RNase OUT (40U ml–1) at 25 1C for 10minutes, followed by
50 1C for 50minutes, according to the manufacturer’s instructions.
The enzyme was heat denatured at 85 1C for 5minutes and the RNA
template removed by treatment with 1 ml RNase H (2U ml–1) at 37 1C
for 20minutes.
Each 25 ml PCR reaction contained 5 ml of 0.2 ng ml–1 comple-
mentary DNA, 1.25ml 20 gene expression assay, 6.25ml H2O, and
12.5ml 2 TaqMan master mix. b-Actin, GAPDH (glyceraldehyde-
3-phosphate dehydrogenase), K5, K6b, K14, K16, and K17 inventor-
ied TaqMan gene expression assays were obtained from Applied
Biosystems (ABI, Foster City, CA). The K6a wild-type and
p.Asn171Lys mutant custom assays (capable of complete discrimi-
nation between the mutant and wild-type K6a targets) are described
in Hickerson et al. (this issue). Samples were analyzed using the ABI
standard 7,500 procedure. The data were analyzed with the Applied
Biosystems Sequence Detection software (version 1.4) and reported
as the relative quantitation using GAPDH mRNA as the endogenous
control. All data points reported are the mean of three replicate
assays and error is reported as SE.
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